Delineating the Dynamic Transcriptome Response of mRNA and microRNA during Zebrafish Heart Regeneration.
Hagen KlettLonny JürgensenPatrick MostMartin BuschFabian GüntherGergana DobrevaFlorian LeuschnerDavid HasselHauke BuschMelanie BörriesPublished in: Biomolecules (2018)
Heart diseases are the leading cause of death for the vast majority of people around the world, which is often due to the limited capability of human cardiac regeneration. In contrast, zebrafish have the capacity to fully regenerate their hearts after cardiac injury. Understanding and activating these mechanisms would improve health in patients suffering from long-term consequences of ischemia. Therefore, we monitored the dynamic transcriptome response of both mRNA and microRNA in zebrafish at 1⁻160 days post cryoinjury (dpi). Using a control model of sham-operated and healthy fish, we extracted the regeneration specific response and further delineated the spatio-temporal organization of regeneration processes such as cell cycle and heart function. In addition, we identified novel (miR-148/152, miR-218b and miR-19) and previously known microRNAs among the top regulators of heart regeneration by using theoretically predicted target sites and correlation of expression profiles from both mRNA and microRNA. In a cross-species effort, we validated our findings in the dynamic process of rat myoblasts differentiating into cardiomyocytes-like cells (H9c2 cell line). Concluding, we elucidated different phases of transcriptomic responses during zebrafish heart regeneration. Furthermore, microRNAs showed to be important regulators in cardiomyocyte proliferation over time.
Keyphrases
- stem cells
- cell cycle
- cell proliferation
- heart failure
- atrial fibrillation
- wound healing
- long non coding rna
- single cell
- rna seq
- public health
- long noncoding rna
- gene expression
- ejection fraction
- transcription factor
- left ventricular
- oxidative stress
- genome wide
- newly diagnosed
- binding protein
- computed tomography
- prognostic factors
- clinical trial
- risk assessment
- angiotensin ii
- contrast enhanced
- double blind